Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ankylosing spondylitis and bowel disease.

Martin Rudwaleit1, Dominique Baeten

  • 1Rheumatology, Charite-Campus Benjamin Franklin, Berlin, Germany.

Best Practice & Research. Clinical Rheumatology
|June 17, 2006
PubMed
Summary

Ankylosing spondylitis (AS) often involves gut inflammation, sometimes linked to inflammatory bowel disease (IBD). Anti-TNF therapy shows promise for treating AS patients with IBD, with infliximab being a preferred option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-label and multi-label classification for disease recognition with special consideration of comorbidities.

BMC medical research methodology·2026
Same author

Bimekizumab Improves Health Status and Work Productivity, With Reduced Productivity Costs, to 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis.

The Journal of rheumatology·2026
Same author

Efficacy of Ixekizumab in Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Level: A Pooled Analysis of Phase III Trials.

Rheumatology and therapy·2026
Same author

Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials.

Rheumatology and therapy·2025
Same author

Targeting fibroblast-like synoviocytes with CDK4/6 inhibitors as a novel, non-immunosuppressive treatment strategy for rheumatoid arthritis.

Clinical and experimental rheumatology·2025
Same author

The Impact of Nonsteroidal Anti-Inflammatory Drugs on Radiographic Spinal Progression in Patients With Axial Spondyloarthritis: 10-Year Results From an Inception Cohort.

Arthritis & rheumatology (Hoboken, N.J.)·2025

Area of Science:

  • Immunology
  • Gastroenterology
  • Rheumatology

Background:

  • Ankylosing spondylitis (AS) frequently co-occurs with inflammatory bowel disease (IBD), affecting 5-10% of AS cases.
  • Many AS patients exhibit subclinical gut inflammation, detectable via endoscopy or histology.
  • Genetic links, including CARD15 mutations, suggest shared inflammatory pathways between AS and IBD.

Purpose of the Study:

  • To explore the association between AS and IBD.
  • To discuss the implications of gut inflammation in AS.
  • To evaluate treatment strategies for AS patients with IBD.

Main Methods:

  • Review of existing literature on AS, IBD, and their associations.
  • Analysis of immunopathological commonalities.
  • Evaluation of therapeutic interventions, including anti-TNF agents.

Main Results:

  • Common inflammatory pathways link gut and joint inflammation in AS and IBD.
  • Non-steroidal anti-inflammatory drugs (NSAIDs) pose risks for IBD reactivation in AS patients.
  • Anti-tumour necrosis factor (TNF) therapies, particularly infliximab, are effective for AS with IBD.

Conclusions:

  • Systematic gut screening is not recommended for asymptomatic AS patients.
  • Anti-TNF therapy offers a safe and effective treatment for AS patients with concomitant IBD.
  • Infliximab is currently the preferred biologic agent for active AS associated with IBD.

Related Experiment Videos